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AllergoOncology: Expression platform development and 
functional profiling of an anti‐HER2 IgE antibody
To the Editor,
Monoclonal antibodies approved for the treatment of cancer belong 
to the IgG class (most often IgG1). However, IgG has limited tissue 
half‐life (2‐3 days), relatively low affinity for cognate Fc receptors 
and the disadvantage of interaction with inhibitory Fcγ receptors, 
abundant in the tumour microenvironment. Conversely, IgE class an‐
tibodies may offer new options for cancer therapy, based on high 
affinity for cognate Fcε receptors expressed on different, often 
tumour‐resident, immune effector cells such as macrophages and 
mast cells, and lack of inhibitory Fc receptors.1 IgE‐mediated tissue 
surveillance functions known to potentiate “allergic” or “pathogen/
parasite‐clearing” immunity could be re‐directed against tissue‐res‐
ident tumours.2,3 IgE antibodies recognizing the tumour‐associated 
antigen folate receptor α (FRα) induced superior immune responses 
in disparate in vivo models, highlighting potential opportunities for 
FRα‐expressing ovarian carcinomas.2 In breast cancer, in vitro stud‐
ies of trastuzumab (IgG1) and an engineered trastuzumab IgE recog‐
nizing the tumour‐associated antigen HER2/neu indicated that IgE 
could complement or possibly improve the clinical performance of 
trastuzumab.4 The first‐in‐class IgE antibody (MOv18) is undergoing 
an early phase clinical trial in patients with FRα‐expressing carcino‐
mas (NCT02546921, www.clini caltr ials.gov).
Despite considerable progres s, pro duction of monoclonal anti‐
bodies remains time‐consuming and labour‐intensive. One reason is 
the requirement for expression of heavy (HC) and light chains (LC) in 
a controlled manner, usually cloned in separate expression vectors 
using enzymatic restriction d igesti on and ligation. This introduces 
experimental variability in e xpress ion procedures and is often in‐
efficient. These limitations also c oncern the study of anti‐allergen 
IgE, where Fabs rather than f ull‐le ngth antibodies are commonly 
expressed and evaluated.5‐7  There fore, antibody cloning systems 
are moving towards utilization of single dual‐expression plasmids (eg 
pcDNA3.3 and pVitro1 hygro‐mcs), to increase antibody production.8
Building upon ours and others' previous methodologies, we re‐
port the efficient transient expression and functional evaluation of 
IgE, exemplified using the variable region sequences of trastuzumab 
and human IgE constant regions (anti‐HER2 IgE).
We employed polymerase incom plete primer extension (PIPE) 
PCR cloning and enzyme‐free a ssembl y of DNA fragments. The 
amino acid sequences of trastuzumab variable light (VL) and heavy 
(VH) chain regions were manually codon‐optimized for a human ex‐
pression host and cloned into a pVitro1‐hygro‐mcs dual‐expression 
vector containing precloned cassettes of the human epsilon HC and 
kappa LC using PIPE PCR cloni ng met hodology (Figure 1A).8 PIPE 
PCR was performed using the pVitro1 plasmid to generate linear PCR 
fragments	with	5′	PIPE	overhangs,	and	trastuzumab	variable	region	
fragments	to	derive	VL	and	VH	region	fragments	with	5′	PIPE	over‐
hangs (DNA fragment sizes by agarose gel electrophoresis, Figure 1B).
Expression was conducted tra nsient ly in human embryonic 
kidney (Expi293F) cells witho ut ant ibiotic selection, in 30 mL 
serum‐free suspension cultures (Figure 1C). Variable region codon 
optimization enhanced antibody yields (~7‐fold; Figure 1D). Peak an‐
tibody concentrations (70‐80 µg/mL) were achieved within 7‐9 days 
(supernatants harvested after  7 day s, Figure 1C,E). After purifica‐
tion, total yields were 60 µg /mL (> 85% purification efficiencies; 
Figure 1F). SDS‐PAGE of pur ified antibodies under nonreducing 
conditions showed a 250 kDa band, l ikely reflecting high antibody 
glycosylation), and reducing conditions revealed two signals (75 kDa 
[HC], 25 kDa [LC]), and a slight signal (100 kDa) likely representing 
different HC glycoforms (Figure 1G). HPLC analysis demonstrated 
assembly of monomeric IgE (Figure 1H).
Like trastuzumab, anti‐HER2 IgE re cognized HER2/neu‐over‐
expressing (BT‐474, ZR75‐30) breast  cancer cells and moderately 
expressing MCF‐10 normal brea st cel ls, and its HER2 antigen 
recognition kinetic profile o n tumo ur cells was comparable to 
trastuzumab (Figure 2A). An ti‐HER 2 IgE and trastuzumab sim‐
ilarly restricted breast cancer cel l viability and epidermal growth 
factor signalling, while addi tion o f antibodies together did not 
improve HER2 signalling inhib ition (Figure 2B,C). Consistent with 
FcεR‐binding MOv18 IgE1,2 ( produc ed in SP2/0 cells), anti‐HER2 
IgE recognized RBL SX‐38 rat basophilic leukaemia cells, express‐
ing the human tetrameric FcεR I(αβγ2 ), and human U937 mono‐
cytes expressing the low‐affinity IgE receptor FcεRII/CD23 upon 
IL‐4 stimulation (Figure 2D). Similar to MOv18 IgE, anti‐HER2 IgE 
recognized FcεRI‐expressing human primary monocytes and anti‐
HER2 IgE binding kinetics to RBL SX‐38 were comparable to those 
of MOv18 IgE (Figure 2).
Anti‐HER2 IgE induced >2‐fold higher ADCC of HER2‐
overexpressing breast cancer cells by unstimulated and IL‐4 
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stimulated U937 effector cells compared with isotype controls 
(Figure 2E). Anti‐HER2 IgE triggered higher ADCC against breast 
cancer cells by peripheral blood mononuclear cells (PBMCs from 
human volunteers, HV, Figure 2E) and >‐fold higher ADCC by 
RBL SX‐38 cells (Figure 2F) compared with isotype controls (see 
Appendix S1).
Anti‐HER2 IgE induced degranulation of RBL SX‐38 cells when 
cross‐linked by polyclonal anti‐IgE on the cell surface (left) or by 
F I G U R E  2   Anti‐HER2 IgE functional characterization. A, Flow cytometric binding/kinetic profiles to breast cancer and normal breast 
(MCF‐10) cells. IgE reduced breast cancer cell viability (B), and HER2/neu signalling (n = 2) (C). D, Flow cytometric binding/kinetic profiles of 
IgE to human FcεR‐expressing: RBL SX‐38 mast cells, U937 monocytes, human monocytes (healthy volunteers, HV; anti‐FRα IgE [MOv18]: 
control). E, F, IgE‐mediated % tumour cell killing (±SD): (E) by U937 (n = 3), human (HV) PBMC (n = 6); (F) by RBL SX‐38. G, RBL SX‐38 
degranulation experiments (β‐hexosaminidase release, Triton X‐100 lysis (Tx100): 100% granule release, representative of n = 2). H, I, 
Anti‐HER2 IgE stimulation in basophil activation test (BAT) (G), and representative flow cytometric dot plots (I), depicting lack of basophil 
activation with anti‐HER2 IgE stimulation
F I G U R E  1   Anti‐HER2 IgE cloning and generation. A, Cloning strategy. 1‐4: Variable region DNA sequence generation. 5: Trastuzumab 
variable	region	plasmids,	pVitro1	plasmid	with	kappa/epsilon	constant	chains	linearized	(PIPE	PCR),	generating	4	fragments	with	5′	PIPE	
overhangs. 6: Linear fragments assembled nonenzymatically (pVitro‐1‐εκ). B, Agarose gel electrophoresis (PIPE fragments). 1: DNA ladder, 2:  
ε‐fragment (4099 bp), 3: κ‐fragment (4119 bp), 4: LC (364 bp), 5: HC (408 bp). C, Expression strategy. D, 7‐day yields following codon 
optimization (representative). Expression before (E) and after (F) purification (±SD, representative of n = 2). G, SDS‐PAGE: 1: protein standard, 2: 
nonreducing, 3: reducing conditions. H, HPLC trace after size exclusion chromatography
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HER2‐expressing tumour cells (right), but not without cross‐linking 
stimulus or with recombinant monomeric antigen (HER2 ectodomain 
[ECD]; Figure 2G). In basophil activation tests (BAT) conducted in 
unfractionated human blood, anti‐HER2 IgE did not induce baso‐
phil activation, monitored by upregulation of the activation marker 
CD63 (Figure 2H,I). Mast cell and basophil tests therefore confirm 
lack of activation with IgE in the absence of cross‐linking stimuli,9 
supporting potential safe administration in human circulation.
IgE immunotherapy may offer a promising approach for cancer 
treatment, contributing to the emerging field of AllergoOncology, 
focused on dissecting interplay between IgE, allergy and malig‐
nancy. The development of efficient platforms for speedy genera‐
tion of full‐length IgE at appreciable yields for numerous evaluations 
to expedite the field remains challenging. Our herein‐described 
multi‐gene cloning, enzyme‐free assembly system for rapid expres‐
sion of functionally active antibody, within 7‐9 days from transfec‐
tion to purification in serum‐free cultures (2 mg purified material 
from 30 mL), readily established even in “small” environments, sur‐
passing previous platforms in expression efficiency, speed (7‐9 days 
vs 4‐6 weeks) and yields (70‐80 mg/mL vs <20‐25 mg/mL),4 meets 
these challenges. IgE maintained Fab‐ and Fc‐mediated properties, 
including antigen and receptor binding, ADCC and degranulation, 
contributing to the most important/prominent antibody function‐
alities. These suggest that under conditions akin to those of tu‐
mours, when encountering high levels of HER2‐expressing cancer 
cells, anti‐HER2 IgE may trigger mast cell activation and antitumour 
effector functions. Importantly, the lack of anti‐HER2 IgE blood 
basophil activation points to diminishing potential safety concerns 
associated with using IgE class antibodies in cancer immunother‐
apy. Our report of transient cloning and rapid antibody production 
greatly facilitates the study of IgE structural and immune functional 
attributes and may find numerous applications in allergy, biotech‐
nology and immunology‐related fields.
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The impact of prescribed fire versus wildfire on the immune 
and cardiovascular systems of children
To the Editor
The increase in wildfires associated with climate change augments 
the impact of air pollution on health in many areas of the country. 
When wildfires occur, there is an increase in asthma attacks and 
associated comorbidities,1,2 especially for asthma hospitalization in 
ages 0‐5 years3 and more recently, it has been shown that there are 
increases in cardiovascular events.4 Given the health risks associ‐
ated with high‐intensity wildfires, there is motivation to increase the 
use of lower intensity prescribed fires. Prescribed burns decrease 
the buildup of flammable vegetation and subsequent fuel for wild‐
fires, mitigating the spread and intensity of wildfires. However, 
prescribed fire raises public concerns because of the additional pol‐
lutant exposure.
Therefore, our objective is to determine whether there are dif‐
ferential health consequences with a prescribed fire vs wildfire. We 
focus on children given their reduced lung size, increased metabolic 
rates, higher respiratory rate, and developing immune systems,5 and 
because in macaque monkeys who are exposed to wildfire smoke 
in infancy, there is associated immune dysregulation and decreased 
lung function in adolescence.6 We hypothesize that the health im‐
pacts of a prescribed fire are less detrimental to the respiratory and 
cardiovascular systems than a wildfire in school‐aged children and 
that T‐cell skewing and epigenetic modulation will occur with expo‐
sure to wildfire more than from exposure to a prescribed fire.
We analyzed data collected from a convenience sample of sub‐
jects (n = 220) over a period of 2 years living in Fresno, CA, all of 
whom were potentially exposed to smoke from fires, which con‐
sisted of similar varieties of coniferous trees, in nearby Yosemite 
National Park. Health questionnaires, blood samples, and vital signs 
were collected, and subjects were selected that had their blood 
drawn 3 months after a prescribed fire or wildfire, because our prior 
research indicates that this time frame is associated with increased 
methylation of the Foxp3 gene.7 Using this criteria, we analyzed data 
from 32 children (median age = 7 [range 7; 8] yrs, 38% asthmatic as 
per NHLBI guidelines) exposed to a prescribed fire 70 miles away 
covering 553 acres in March, 2015, and 36 children (median age = 8 
[range 7; 8] yrs, 25% asthmatic) exposed to a wildfire 70 miles away 
covering 415 acres in September 2015. A control group of 18 chil‐
dren was also compared (median age = 8 [range 7; 8] yrs; 21% asth‐
matic), who had no obvious exposure to wildfires or prescribed fire 
and were living in the San Francisco Bay area, where pollution levels 
